ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2007

ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2007

Västra Frölunda, Sweden, August 8, 2007

• Net revenue of SEK 8.7 million (3.0)*
• Net loss of SEK -7.7 million (-30.7)
• Net loss of SEK -6.1 million (-19.1) excluding a non-recurring item of SEK
-1.6 million (-11.6)
• Earnings per share, including non-recurring item, of SEK -0.13 (SEK -0.52)
• Sales for Artelon® CMC Spacer - approximately 2,100 (900) units were sold to
end-customers, of which 800 (500) were during Q2 2007
• Since the launch approximately 5,000 patients have been treated with Artelon®
implants 
• FDA clearance for marketing for Artelon® CMC Spacer Arthro and Artelon® STT
Spacer
• A head of marketing has been appointed and will commence on October 1

* Figures in brackets refer to the corresponding period last year. 

Artimplant will host a conference call in Swedish at 2:30 PM Central European
Time (GMT+1). Log on details are available on www.artimplant.com.

Please note that Artimplant´s nine-monthly report will be presented one day
later than earlier communicated on November 9, 2007.

For additional information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.